Micafungin im Vergleich zu Caspofungin bei der Behandlung von invasiven Candida-Infektionen: Eine Kosteneffektivitätsanalyse für Deutschland
Authors:
- 1 December 2010
- journal article
- Published by Springer Nature in PharmacoEconomics German Research Articles
- Vol. 8 (2) , 71-83
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Epidemiology of Invasive Mycoses in North AmericaCritical Reviews in Microbiology, 2010
- The changing face of epidemiology of invasive fungal disease in EuropeMycoses, 2009
- Epidemiology of Invasive Candidiasis: a Persistent Public Health ProblemClinical Microbiology Reviews, 2007
- Invasive CandidiasisInfectious Disease Clinics of North America, 2006
- Candidaemia in Europe: epidemiology and resistanceInternational Journal of Antimicrobial Agents, 2006
- The Epidemiology and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: A Propensity AnalysisClinical Infectious Diseases, 2005
- Excess Mortality, Hospital Stay, and Cost Due to Candidemia: A Case-Control Study Using Data From Population-Based Candidemia SurveillanceInfection Control & Hospital Epidemiology, 2005
- Attributable Mortality of Nosocomial Candidemia, RevisitedClinical Infectious Diseases, 2003
- Comparison of Caspofungin and Amphotericin B for Invasive CandidiasisNew England Journal of Medicine, 2002
- Invasive Aspergillosis Disease Spectrum, Treatment Practices, and OutcomesMedicine, 2000